JPRN-UMIN000018233
Completed
Phase 2
Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer. - Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.
Conditionson-small-cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small-cell lung cancer
- Sponsor
- Shimane university hospital
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Brain metastasis with the symptom 2\)Active interstitial pneumonia or pulmonary fibrosis 3\)Body fluid retention to need waste fluid 4\)Hypersensitivity for paclitaxel or albumin 5\)Pregnant or nursing female or man without the intention of the contraception 6\)Active concomitant malignancy 7\)Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012114Osaka City General Hospital30
Recruiting
Not Applicable
Phase2 study of Nab-Paclitaxel in patients with unresectable or advanced squamous cell lung cancersquamous cell lung cancerJPRN-UMIN000014558Tottori University Faculty of Medicine27
Completed
Not Applicable
Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung CancerTreated patients with advanced non-small cell lung cancerJPRN-UMIN000015841Tohoku Medical and Pharmaceutical University30
Completed
Phase 2
Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.urothelial cancerJPRN-UMIN000015260Department of Urology, Saitama Medical Center, Saitama Medical University5
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22